Co-Authors
This is a "connection" page, showing publications co-authored by FREDRICK B HAGEMEISTER and FRANCESCO TURTURRO.
Connection Strength
0.632
-
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023 04 11; 7(7):1137-1145.
Score: 0.056
-
The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461.
Score: 0.039
-
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108.
Score: 0.038
-
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870.
Score: 0.038
-
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477.
Score: 0.037
-
Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844.
Score: 0.037
-
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758.
Score: 0.036
-
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299.
Score: 0.035
-
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.
Score: 0.035
-
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151.
Score: 0.035
-
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016 07; 27(7):1317-23.
Score: 0.034
-
Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016 05; 27(5):895-901.
Score: 0.034
-
Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8.
Score: 0.034
-
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
Score: 0.032
-
Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82.
Score: 0.032
-
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.
Score: 0.031
-
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
Score: 0.030
-
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Feb; 136(3):439-47.
Score: 0.018